文献速递前列腺癌

双相雄激素治疗联合奥拉帕利治疗转移性去势抵抗性前列腺癌男性患者

Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-12-23

这项单中心II期试验评估奥拉帕利联合双相雄激素治疗(BAT)在转移性去势抵抗性前列腺癌(mCRPC)患者中的疗效,计划入组30例,实际入组36例,其中6例在疗效评估前退出。意向治疗(ITT)队列12周时PSA50应答率为31%(11/36,95%CI 17-48%),研究期间任意时间PSA50应答率为44%(16/36,95%CI 28-62%);中位随访19个月,中位临床/影像学无进展生存期为13.0个月(95%CI 7-17)。临床结局与同源重组修复(HRR)基因突变状态无关。

要点

  • 奥拉帕利联合BAT在mCRPC中显示较高应答率:ITT队列12周PSA50应答率31%,任意时间44%。
  • ITT队列中位临床/影像学无进展生存期为13.0个月(95%CI 7-17)。
  • 临床获益与HRR基因突变状态无关。

核心结论

  • BAT联合奥拉帕利与高应答率和长无进展生存期相关,且临床获益与HRR基因突变状态无关。

研究设计与样本

  • 单中心II期试验,测试奥拉帕利联合BAT(环丙酸/庚酸睾酮400 mg每28天)并持续雄激素剥夺治疗。
  • 计划入组30例(有/无同源重组修复[HRR]基因突变者比例相等)接受阿比特龙和/或恩扎卢胺治疗后的mCRPC患者;实际入组36例,6例在疗效评估前退出。
  • 主要终点为12周时PSA50应答率(PSA较基线下降≥50%),主要分析采用意向治疗(ITT)队列,早期退出者计为非应答者;次要/探索性分析在治疗超过12周的患者(可评估应答队列)中进行。

主要发现

  • ITT队列12周时PSA50应答率为11/36(31%;95%CI 17-48%),研究期间任意时间PSA50应答率为16/36(44%,95%CI 28-62%)。
  • 中位随访19个月,ITT队列中位临床/影像学无进展生存期为13.0个月(95%CI 7-17)。
  • 无论HRR基因突变状态如何,临床结局相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bipolar androgen therapy (BAT) results in rapid fluctuation of testosterone (T) between near-castrate and supraphysiological levels and has shown promise in metastatic castration-resistant prostate cancer (mCRPC). Its clinical effects may be mediated through induction of DNA damage, and preclinical studies suggest synergy with PARP inhibitors. PATIENTS AND METHODS: This was a single-center, Phase II trial testing olaparib plus BAT (T cypionate/enanthate 400 mg every 28 days) with ongoing androgen deprivation. Planned recruitment was 30 subjects (equal proportions with/without homologous recombination repair [HRR] gene mutations) with mCRPC post abiraterone and/or enzalutamide. The primary objective was to determine PSA50 response (PSA decline ≥50% from baseline) rate at 12-weeks. The primary analysis utilized the entire (intent-to-treat [ITT]) cohort, with those dropping out early counted as non-responders. Secondary/exploratory analyses were in those treated beyond 12-weeks (response-evaluable cohort). RESULTS: Thirty-six patients enrolled and 6 discontinued prior to response assessment. In the ITT cohort, PSA50 response rate at 12-weeks was 11/36 (31%; 95% CI 17-48%), and 16/36 (44%, 95% CI 28-62%) had a PSA50 response at any time on-study. After a median follow-up of 19 months, the median clinical/radiographic progression-free survival in the ITT cohort was 13.0 months (95% CI 7-17). Clinical outcomes were similar regardless of HRR gene mutational status. CONCLUSIONS: BAT plus olaparib is associated with high response rates and long PFS. Clinical benefit was observed regardless of HRR gene mutational status.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Schweizer MT, Gulati R, Yezefski T, et al. Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022. PMID: 36564459. doi:10.1038/s41391-022-00636-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。